Mereo BioPharma Announces Successful Type B Meeting with U.S. FDA and Outlines Accelerated Approval Pathway for Navicixizumab in Advanced Ovarian Cancer

Stock Information for Mereo BioPharma Group plc

Loading

Please wait while we load your information from QuoteMedia.